Agile Therapeutics, Inc.-Product Pipeline Review-2015

Agile Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06886CDB
  • |
  • Pages: 28
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Agile Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Agile Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Agile Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agile Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Agile Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Agile Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Agile Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Agile Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Agile Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Agile Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Agile Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agile Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Agile Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Agile Therapeutics, Inc. Snapshot 4

Agile Therapeutics, Inc. Overview 4

Key Information 4

Key Facts 4

Agile Therapeutics, Inc.-Research and Development Overview 5

Key Therapeutic Areas 5

Agile Therapeutics, Inc.-Pipeline Review 6

Pipeline Products by Stage of Development 6

Pipeline Products-Monotherapy 7

Pipeline Products-Combination Treatment Modalities 8

Agile Therapeutics, Inc.-Pipeline Products Glance 9

Agile Therapeutics, Inc.-Late Stage Pipeline Products 9

Phase III Products/Combination Treatment Modalities 9

Agile Therapeutics, Inc.-Clinical Stage Pipeline Products 10

Phase II Products/Combination Treatment Modalities 10

Phase I Products/Combination Treatment Modalities 11

Agile Therapeutics, Inc.-Early Stage Pipeline Products 12

Discovery Products/Combination Treatment Modalities 12

Agile Therapeutics, Inc.-Drug Profiles 13

(ethinyl estradiol + levonorgestrel) 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

AG-200 ER 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

levonorgestrel 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

AG-200 SP 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Agile Therapeutics, Inc.-Pipeline Analysis 19

Agile Therapeutics, Inc.-Pipeline Products by Target 19

Agile Therapeutics, Inc.-Pipeline Products by Route of Administration 20

Agile Therapeutics, Inc.-Pipeline Products by Molecule Type 21

Agile Therapeutics, Inc.-Pipeline Products by Mechanism of Action 22

Agile Therapeutics, Inc.-Recent Pipeline Updates 23

Agile Therapeutics, Inc.-Locations And Subsidiaries 26

Head Office 26

Appendix 27

Methodology 27

Coverage 27

Secondary Research 27

Primary Research 27

Expert Panel Validation 27

Contact Us 27

Disclaimer 28

List of Tables

Agile Therapeutics, Inc., Key Information 4

Agile Therapeutics, Inc., Key Facts 4

Agile Therapeutics, Inc.-Pipeline by Indication, 2015 5

Agile Therapeutics, Inc.-Pipeline by Stage of Development, 2015 6

Agile Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 7

Agile Therapeutics, Inc.-Combination Treatment Modalities in Pipeline, 2015 8

Agile Therapeutics, Inc.-Phase III, 2015 9

Agile Therapeutics, Inc.-Phase II, 2015 10

Agile Therapeutics, Inc.-Phase I, 2015 11

Agile Therapeutics, Inc.-Discovery, 2015 12

Agile Therapeutics, Inc.-Pipeline by Target, 2015 19

Agile Therapeutics, Inc.-Pipeline by Route of Administration, 2015 20

Agile Therapeutics, Inc.-Pipeline by Molecule Type, 2015 21

Agile Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 22

Agile Therapeutics, Inc.-Recent Pipeline Updates, 2015 23

List of Figures

Agile Therapeutics, Inc.-Pipeline by Stage of Development, 2015 6

Agile Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 7

Agile Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 19

Agile Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 20

Agile Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 21

Agile Therapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Agile Therapeutics, Inc.; Agile Therapeutics, Inc. - Key Therapeutics; Agile Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Agile Therapeutics, Inc. - News; Agile Therapeutics, Inc. - Latest Updates; Agile Therapeutics, Inc. - Pipeline; Agile Therapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 100395
Site License
USD 3000 INR 200790
Corporate User License
USD 4500 INR 301185



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]